Scholarlink

Background <p>The intravesical Bacillus Calmette-Guérin (BCG) immunotherapy in Bladder Cancer (BC) is the standard adjuvant therapy with challenges such as limited efficacy and recurrence. We aimed to assess the synergistic antitumor effects of melatonin and BCG in vivo.</p> Methods <p>The xerograph C57BL/6J mice model developed with injection of 2.0 × 10⁶ MB49 cells. After two weeks, mice were grouped: control (PBS + DMSO), melatonin (200&#xa0;µg), high-dose BCG (HDBCG, 3.0 × 10⁶ CFU), melatonin with low-dose BCG (LDBCG + MLT, 1.0 × 10⁶ CFU), and melatonin with HDBCG (HDBCG + MLT). At the end of the study the histologically was assessed for proliferation, microangiogenesis, and inflammation. Complete blood counts (CBC), Erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) were measured. Gene expression was determined by real-time PCR.</p> Results <p>The HDBCG + MLT decreased tumor weight and volume compared with to LDBCG + MLT and HDBCG alone (<i>p</i> &lt; 0.05). Histopathology showed HDBCG + MLT increased apoptosis and immune cell infiltration, with reduced mitotic figures and micro-vessel density. Serological analysis indicates HDBCG alone induced significant increases in WBC count and CRP levels, whereas co-administration of melatonin markedly attenuated these elevations (<i>p</i> &lt; 0.05) without altering ESR. In HDBCG + MLT group, <i>BAX</i>, P53, <i>Syn3</i>,<i> E-cadherin</i>,<i> IL-2</i>,<i> IL-10</i>, and IFN-<i>γ</i> upregulated, while BCL-2, <i>VEGF-A</i>, <i>HIF-1α</i>, and <i>TGF-α</i> downregulated.</p> Conclusions <p>Co-administration of melatonin enhanced the antitumor efficacy of BCG immunotherapy in BC, as evidenced by increased apoptosis and immune cell infiltration, along with marked suppression of angiogenesis and the EMT pathway.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Melatonin enhances the antitumor and immunomodulatory effects of Bacillus Calmette-Guérin immunotherapy in a murine bladder cancer model

  • 期刊论文

  • 发表日期：

    2026年4月10日

查看全文
  • Iman Menbari Oskouie,
  • Fatemeh Khatami,
  • Gholamreza Mesbah,
  • Leila Zareian Baghdadabad,
  • Nooshin Eidinezhad,
  • Rahil Mashhadi,
  • Parisa Zahmatkesh,
  • Ramin Heshamt,
  • Parsa Nikoofar,
  • Seyed Mohammad Kazem Aghamir

摘要

Background

The intravesical Bacillus Calmette-Guérin (BCG) immunotherapy in Bladder Cancer (BC) is the standard adjuvant therapy with challenges such as limited efficacy and recurrence. We aimed to assess the synergistic antitumor effects of melatonin and BCG in vivo.

Methods

The xerograph C57BL/6J mice model developed with injection of 2.0 × 10⁶ MB49 cells. After two weeks, mice were grouped: control (PBS + DMSO), melatonin (200 µg), high-dose BCG (HDBCG, 3.0 × 10⁶ CFU), melatonin with low-dose BCG (LDBCG + MLT, 1.0 × 10⁶ CFU), and melatonin with HDBCG (HDBCG + MLT). At the end of the study the histologically was assessed for proliferation, microangiogenesis, and inflammation. Complete blood counts (CBC), Erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) were measured. Gene expression was determined by real-time PCR.

Results

The HDBCG + MLT decreased tumor weight and volume compared with to LDBCG + MLT and HDBCG alone (p < 0.05). Histopathology showed HDBCG + MLT increased apoptosis and immune cell infiltration, with reduced mitotic figures and micro-vessel density. Serological analysis indicates HDBCG alone induced significant increases in WBC count and CRP levels, whereas co-administration of melatonin markedly attenuated these elevations (p < 0.05) without altering ESR. In HDBCG + MLT group, BAX, P53, Syn3, E-cadherin, IL-2, IL-10, and IFN-γ upregulated, while BCL-2, VEGF-A, HIF-1α, and TGF-α downregulated.

Conclusions

Co-administration of melatonin enhanced the antitumor efficacy of BCG immunotherapy in BC, as evidenced by increased apoptosis and immune cell infiltration, along with marked suppression of angiogenesis and the EMT pathway.